1. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
- Author
-
Musto, P, Simeon, V, Martorelli, M C, Petrucci, M T, Cascavilla, N, Di Raimondo, F, Caravita, T, Morabito, F, Offidani, M, Olivieri, A, Benevolo, G, Mina, R, Guariglia, R, D'Arena, G, Mansueto, G, Filardi, N, Nobile, F, Levi, A, Falcone, A, and Cavalli, M
- Subjects
PLASMA cell leukemia ,DEXAMETHASONE ,DRUG dosage ,MULTIPLE myeloma ,LEUKEMIA treatment - Abstract
The article presents the first prospective study of initial treatment in primary plasma cell leukemia (PPCL) based on a combination of lenalidomide and low-dose dexamethasone (Ld). It notes the capability of Ld to ameliorate overall response rate (ORR) and at least very good partial response (VGPR) rate when compared with any other reported treatment conducted without novel drugs. It also reveals that PPCL patients have more compromised marrow and renal function than multiple myeloma patients.
- Published
- 2014
- Full Text
- View/download PDF